Literature DB >> 8815124

Serum rotavirus neutralizing-antibody titers compared by plaque reduction and enzyme-linked immunosorbent assay-based neutralization assays.

R L Ward1, A Z Kapikian, K M Goldberg, D R Knowlton, M W Watson, R Rappaport.   

Abstract

Comparisons in rotavirus neutralizing-antibody responses were made with sera collected from vaccinated infants. The methods were a plaque reduction assay and a new enzyme-linked immunosorbent assay-based neutralization assay. Agreement of 94% was found in detecting at least fourfold seroresponses, and correlation coefficients between titers obtained by the two methods showed excellent agreement, indicating that either could be used reliably.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8815124      PMCID： PMC228933          DOI： 10.1128/jcm.34.4.983-985.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  18 in total

1.  Neonatal calf diarrhoea: identification of a reovirus-like (rotavirus) agent in faeces by immunofluorescence and immune electron microscopy.

Authors:  J C Bridger; G N Woode
Journal:  Br Vet J       Date:  1975 Sep-Oct

Review 2.  Rotavirus gene structure and function.

Authors:  M K Estes; J Cohen
Journal:  Microbiol Rev       Date:  1989-12

3.  Reassortant rotaviruses as potential live rotavirus vaccine candidates.

Authors:  K Midthun; H B Greenberg; Y Hoshino; A Z Kapikian; R G Wyatt; R M Chanock
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

4.  Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4.

Authors:  K Midthun; Y Hoshino; A Z Kapikian; R M Chanock
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

5.  Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants.

Authors:  D I Bernstein; V E Smith; D S Sander; K A Pax; G M Schiff; R L Ward
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

6.  Antigenic relationships among human rotaviruses as determined by outer capsid protein VP4.

Authors:  M Gorziglia; G Larralde; A Z Kapikian; R M Chanock
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

7.  Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3.

Authors:  H F Clark; F E Borian; S A Plotkin
Journal:  J Infect Dis       Date:  1990-06       Impact factor: 5.226

8.  Local and systemic antibody response to rotavirus WC3 vaccine in adult volunteers.

Authors:  D I Bernstein; M A Kacica; M M McNeal; G M Schiff; R L Ward
Journal:  Antiviral Res       Date:  1989-12       Impact factor: 5.970

9.  Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines--report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group.

Authors:  M B Rennels; R I Glass; P H Dennehy; D I Bernstein; M E Pichichero; E T Zito; M E Mack; B L Davidson; A Z Kapikian
Journal:  Pediatrics       Date:  1996-01       Impact factor: 7.124

10.  Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children.

Authors:  T Vesikari; E Isolauri; A Delem; E D'Hondt; F E André; G Zissis
Journal:  Lancet       Date:  1983-10-08       Impact factor: 79.321
View more
  8 in total

1.  Neutralization assay for human group C rotaviruses using a reverse passive hemagglutination test for endpoint determination.

Authors:  R Fujii; M Kuzuya; M Hamano; H Ogura; M Yamada; T Mori
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Postdose 3 G1 serum neutralizing antibody as correlate of protection for pentavalent rotavirus vaccine.

Authors:  G Frank Liu; Darcy Hille; Susan S Kaplan; Michelle G Goveia
Journal:  Hum Vaccin Immunother       Date:  2017-08-24       Impact factor: 3.452

3.  Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.

Authors:  Suvi Lappalainen; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

4.  Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules.

Authors:  Romina Libster; Monica McNeal; Emmanuel B Walter; Andi L Shane; Patricia Winokur; Gretchen Cress; Andrea A Berry; Karen L Kotloff; Kwabena Sarpong; Christine B Turley; Christopher J Harrison; Barbara A Pahud; Jyothi Marbin; John Dunn; Jill El-Khorazaty; Jill Barrett; Kathryn M Edwards
Journal:  Pediatrics       Date:  2016-01-28       Impact factor: 7.124

Review 5.  Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings.

Authors:  E Clarke; U Desselberger
Journal:  Mucosal Immunol       Date:  2014-12-03       Impact factor: 7.313

6.  Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.

Authors:  Suvi Lappalainen; Ana Ruth Pastor; Kirsi Tamminen; Vanessa López-Guerrero; Fernando Esquivel-Guadarrama; Laura A Palomares; Timo Vesikari; Vesna Blazevic
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.

Authors:  Michelle J Groome; Lee Fairlie; Julie Morrison; Alan Fix; Anthonet Koen; Maysseb Masenya; Lisa Jose; Shabir A Madhi; Nicola Page; Monica McNeal; Len Dally; Iksung Cho; Maureen Power; Jorge Flores; Stanley Cryz
Journal:  Lancet Infect Dis       Date:  2020-04-03       Impact factor: 25.071

8.  Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.

Authors:  Kirsi Tamminen; Suvi Lappalainen; Leena Huhti; Timo Vesikari; Vesna Blazevic
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.